Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: Implications for the mechanism of this interaction

Alberto Sobrero, Antonella Romanini, Orsolina Russello, Angelo Nicolin, Riccardo Rosso, Joseph R. Bertino

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The new folate antagonist trimetrexate is an inhibitor of dihydrofolate reductase, but unlike methotrexate (MTX) it is not polyglutamylated. We have compared the cell killing effects of MTX and trimetrexate/5-fluorouracil (FUra) and 5-fluoro-2′-deoxyuridine (FdUrd) combinations on HCT-8 cells in vitro, in an attempt to explore indirectly the role of polyglutamylation of the antifol in determining the known sequence-dependent synergism between MTX and FUra. The comparisons were made in a number of equitoxic concentrations and times of exposure. Trimetrexate given for 4, 24 or 48 h followed by FUra, for 4, 24 or 196 h, produced synergistic HTC-8 cell kill, whereas antagonism was observed when FUra preceded or was given simultaneously with trimetrexate. The degree of interaction was essentially identical to those obtained when MTX was combined with FUra. The interactions between MTX/FdUrd and trimetrexate/FdUrd were also similar: synergistic cell kill resulted from the sequences trimetrexate or MTX followed by FdUrd, while additive effects were produced by trimetrexate or MTX + FdUrd combinations or FdUrd followed by MTX or trimetrexate. Because the same interactions observed with MTX/FUra or FdUrd combinations were also obtained when trimetrexate was combined with the fluoropyrimidines, it is unlikely that polyglutamylation of the antifols plays a significant role in determining the different sequence-dependent effects of these antimetabolites. However, these studies do not rule out the possibility that increased levels of dihydrofolate polyglutamates increase fluoropyrimidine cytotoxicity.

Original languageEnglish
Pages (from-to)977-982
Number of pages6
JournalEuropean Journal of Cancer and Clinical Oncology
Volume25
Issue number6
DOIs
Publication statusPublished - 1989

Fingerprint

Trimetrexate
Methotrexate
Deoxyuridine
Fluorouracil
Polyglutamic Acid
Folic Acid Antagonists
Antimetabolites
Folic Acid

ASJC Scopus subject areas

  • Oncology

Cite this

Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines : Implications for the mechanism of this interaction. / Sobrero, Alberto; Romanini, Antonella; Russello, Orsolina; Nicolin, Angelo; Rosso, Riccardo; Bertino, Joseph R.

In: European Journal of Cancer and Clinical Oncology, Vol. 25, No. 6, 1989, p. 977-982.

Research output: Contribution to journalArticle

Sobrero, Alberto ; Romanini, Antonella ; Russello, Orsolina ; Nicolin, Angelo ; Rosso, Riccardo ; Bertino, Joseph R. / Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines : Implications for the mechanism of this interaction. In: European Journal of Cancer and Clinical Oncology. 1989 ; Vol. 25, No. 6. pp. 977-982.
@article{4890d37d130e423bbfd1cc36a158658a,
title = "Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: Implications for the mechanism of this interaction",
abstract = "The new folate antagonist trimetrexate is an inhibitor of dihydrofolate reductase, but unlike methotrexate (MTX) it is not polyglutamylated. We have compared the cell killing effects of MTX and trimetrexate/5-fluorouracil (FUra) and 5-fluoro-2′-deoxyuridine (FdUrd) combinations on HCT-8 cells in vitro, in an attempt to explore indirectly the role of polyglutamylation of the antifol in determining the known sequence-dependent synergism between MTX and FUra. The comparisons were made in a number of equitoxic concentrations and times of exposure. Trimetrexate given for 4, 24 or 48 h followed by FUra, for 4, 24 or 196 h, produced synergistic HTC-8 cell kill, whereas antagonism was observed when FUra preceded or was given simultaneously with trimetrexate. The degree of interaction was essentially identical to those obtained when MTX was combined with FUra. The interactions between MTX/FdUrd and trimetrexate/FdUrd were also similar: synergistic cell kill resulted from the sequences trimetrexate or MTX followed by FdUrd, while additive effects were produced by trimetrexate or MTX + FdUrd combinations or FdUrd followed by MTX or trimetrexate. Because the same interactions observed with MTX/FUra or FdUrd combinations were also obtained when trimetrexate was combined with the fluoropyrimidines, it is unlikely that polyglutamylation of the antifols plays a significant role in determining the different sequence-dependent effects of these antimetabolites. However, these studies do not rule out the possibility that increased levels of dihydrofolate polyglutamates increase fluoropyrimidine cytotoxicity.",
author = "Alberto Sobrero and Antonella Romanini and Orsolina Russello and Angelo Nicolin and Riccardo Rosso and Bertino, {Joseph R.}",
year = "1989",
doi = "10.1016/0277-5379(89)90157-0",
language = "English",
volume = "25",
pages = "977--982",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "6",

}

TY - JOUR

T1 - Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines

T2 - Implications for the mechanism of this interaction

AU - Sobrero, Alberto

AU - Romanini, Antonella

AU - Russello, Orsolina

AU - Nicolin, Angelo

AU - Rosso, Riccardo

AU - Bertino, Joseph R.

PY - 1989

Y1 - 1989

N2 - The new folate antagonist trimetrexate is an inhibitor of dihydrofolate reductase, but unlike methotrexate (MTX) it is not polyglutamylated. We have compared the cell killing effects of MTX and trimetrexate/5-fluorouracil (FUra) and 5-fluoro-2′-deoxyuridine (FdUrd) combinations on HCT-8 cells in vitro, in an attempt to explore indirectly the role of polyglutamylation of the antifol in determining the known sequence-dependent synergism between MTX and FUra. The comparisons were made in a number of equitoxic concentrations and times of exposure. Trimetrexate given for 4, 24 or 48 h followed by FUra, for 4, 24 or 196 h, produced synergistic HTC-8 cell kill, whereas antagonism was observed when FUra preceded or was given simultaneously with trimetrexate. The degree of interaction was essentially identical to those obtained when MTX was combined with FUra. The interactions between MTX/FdUrd and trimetrexate/FdUrd were also similar: synergistic cell kill resulted from the sequences trimetrexate or MTX followed by FdUrd, while additive effects were produced by trimetrexate or MTX + FdUrd combinations or FdUrd followed by MTX or trimetrexate. Because the same interactions observed with MTX/FUra or FdUrd combinations were also obtained when trimetrexate was combined with the fluoropyrimidines, it is unlikely that polyglutamylation of the antifols plays a significant role in determining the different sequence-dependent effects of these antimetabolites. However, these studies do not rule out the possibility that increased levels of dihydrofolate polyglutamates increase fluoropyrimidine cytotoxicity.

AB - The new folate antagonist trimetrexate is an inhibitor of dihydrofolate reductase, but unlike methotrexate (MTX) it is not polyglutamylated. We have compared the cell killing effects of MTX and trimetrexate/5-fluorouracil (FUra) and 5-fluoro-2′-deoxyuridine (FdUrd) combinations on HCT-8 cells in vitro, in an attempt to explore indirectly the role of polyglutamylation of the antifol in determining the known sequence-dependent synergism between MTX and FUra. The comparisons were made in a number of equitoxic concentrations and times of exposure. Trimetrexate given for 4, 24 or 48 h followed by FUra, for 4, 24 or 196 h, produced synergistic HTC-8 cell kill, whereas antagonism was observed when FUra preceded or was given simultaneously with trimetrexate. The degree of interaction was essentially identical to those obtained when MTX was combined with FUra. The interactions between MTX/FdUrd and trimetrexate/FdUrd were also similar: synergistic cell kill resulted from the sequences trimetrexate or MTX followed by FdUrd, while additive effects were produced by trimetrexate or MTX + FdUrd combinations or FdUrd followed by MTX or trimetrexate. Because the same interactions observed with MTX/FUra or FdUrd combinations were also obtained when trimetrexate was combined with the fluoropyrimidines, it is unlikely that polyglutamylation of the antifols plays a significant role in determining the different sequence-dependent effects of these antimetabolites. However, these studies do not rule out the possibility that increased levels of dihydrofolate polyglutamates increase fluoropyrimidine cytotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=0024371816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024371816&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(89)90157-0

DO - 10.1016/0277-5379(89)90157-0

M3 - Article

C2 - 2526736

AN - SCOPUS:0024371816

VL - 25

SP - 977

EP - 982

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 6

ER -